Technology
Health
Biotechnology

Erytech Pharma

$8.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) Today

Why Robinhood?

You can buy or sell Erytech Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Erytech Pharma S.A. American Depositary Shares, also called Erytech Pharma, is a biopharmaceutical company, which develops medical products. Read More It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Employees
114
Headquarters
Lyon, Rhone-Alpes
Founded
2004
Market Cap
154.24M
Price-Earnings Ratio
Dividend Yield
Average Volume
1.74K
High Today
Low Today
Open Price
Volume
0.00
52 Week High
$21.62
52 Week Low
$5.45

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Cancer Prevention
Pharmaceutical
2016 IPO

News

Seeking AlphaMar 12

ERYTECH Pharma S.A. (ERYP) CEO Gil Beyen on Q4 2018 Results - Earnings Call Transcript

ERYTECH Pharma S.A. (NASDAQ:ERYP) Q4 2018 Earnings Conference Call March 12, 2019 8:30 AM ET Company Participants Gil Beyen - Chief Executive Officer Eric Soyer - Chief Financial Officer and Chief Operating Officer Iman El Hariry - Chief Medical Officer Conference Call Participants Dylan van Haaften - NIBC Operator Good day, ladies and gentlemen. And welcome to the ERYTECH Fourth Quarter and Full Year 2018 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructi...

9
MarketBeatMar 2

Stock Price, News, & Analysis for Erytech Pharma

ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United...

1

Earnings

-$0.61
-$0.54
-$0.48
-$0.41
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
-$0.51 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.